Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 31 of 65 · 3112 articles
If you’re stable on ustekinumab for Crohn’s disease, this multicenter study found that switching to an approved biosimilar produced similar 6-month remission and safety outcomes to staying on the original product. That...
PG is often linked with IBD and other systemic conditions, so approaches that treat the underlying comorbidity can improve ulcer healing and lower relapse risk. Patients with IBD who develop PG may benefit from therapies...
Researchers report a modest association between higher estimated dietary sodium and greater odds of several IL-17–mediated diseases, while IBD showed a small inverse association. Patients may be interested because it...
Researchers are exploring natural compounds that might reduce intestinal inflammation and rebalance the gut microbiome. If translatable to humans, such approaches could inform new treatments or adjunctive therapies for...
The review connects UC pathological features to specific drug-delivery design needs, which could guide development of therapies that reach and act effectively in inflamed colon tissue. For people with UC, better-targeted...
IBD can cause cognitive and neurological symptoms. This preclinical study suggests a flavonoid-rich Chrysanthemum extract reduced colitis and related cognitive deficits in mice by changing the gut microbiota and...
Cure8 could only read part of this source from The American Journal of Gastroenterology, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and...
This study tests a common clinical question: whether increasing vedolizumab frequency helps patients who show no endoscopic response after 6 months. The results suggest intensification raised drug levels but did not...
This study will gather real‑world effectiveness and patient‑reported outcome data for guselkumab in adults with moderate‑to‑severe Crohn’s disease or ulcerative colitis, which may help clinicians and patients understand...
Patients and clinicians considering guselkumab for Crohn’s disease or ulcerative colitis may gain real-world evidence on how the drug performs across treatment lines and subgroups over up to 96 weeks. The study will...
This registry will track long-term safety and clinical outcomes in children with IBD, with a focus on infliximab (an anti‑TNF biologic) versus non‑biologic therapies. Long follow-up could help identify uncommon or late...
Phase 3 testing of guselkumab (an IL-23–targeting biologic) in moderately to severely active ulcerative colitis could expand treatment options if the trial meets its endpoints and shows an acceptable safety profile. The...
This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...
Sleep problems are common in Crohn’s disease and may worsen symptoms, pain, and inflammation. This trial is testing whether a remotely delivered insomnia treatment is feasible and whether improving sleep could also...
AI tools are being tailored to IBD care; this study suggests supervised fine-tuned LLMs may help with patient communication and workflow but currently lack reliable diagnostic accuracy. Patients and clinicians should...
Understanding PTMs may help researchers identify new biomarkers or therapeutic targets for ulcerative colitis, which could eventually lead to better treatments or tests. For people with UC, this explains part of why...
The study identifies a plant-derived compound (curcumol) that reduced inflammation, mucosal injury, and some microbiome/metabolome disturbances in a mouse model of ulcerative colitis and links these effects to...
This study reports preclinical evidence that an herbal extract (EGST) reduced inflammation and epithelial cell ferroptosis in a mouse model of ulcerative colitis and in cell experiments, implicating the PPARγ/GPX4...
People with IBD and their clinicians may want to be aware of possible higher rates of some non-gastrointestinal cancers (thyroid, kidney, prostate) and of factors linked to higher risk such as long-term steroid use,...
Registries that automatically extract clinical data with AI/NLP can speed research, help identify patient cohorts for studies or trials, and may eventually support better clinical decision-making for people with IBD....
The study identifies abnormal epithelial cell–death signaling that persists despite current therapies and may help explain why many people with IBD relapse. If validated, these pathways could point to new biomarkers or...
If you have overweight or obesity, this study suggests measurable blood proteins linked to inflammation may be associated with higher future risk of ulcerative colitis. Identifying such markers could help research on...
Researchers are exploring new anti-inflammatory molecules for ulcerative colitis. Mechanistic data showing inhibition of macrophage M1 polarization, MAPK signaling, and antioxidant activity may help prioritize VpG for...
Butyrate supports intestinal health and is often low in IBD. A single oral compound that reliably restores luminal butyrate could — if proven safe and effective in humans — offer a new way to treat ulcerative colitis or...
Researchers working on IBD molecular mechanisms or biomarker discovery may find this AI-driven approach useful because it can detect temporal gene-expression patterns and suggest pathways linked to treatment response...
A new subcutaneous induction option for risankizumab could make starting this biologic easier for many adults with moderate-to-severe Crohn's disease by avoiding infusions, potentially increasing access and convenience.
Chronic pain is common in people with Crohn’s disease and ulcerative colitis and can persist despite controlling gut inflammation. Brief online pain-education programs could offer a low-burden, scalable way to reduce...
New investigational therapy AZD7798 is being tested specifically for mucosal repair in people with active ileal Crohn’s disease who have an ileostomy — a group often excluded from other trials. Trial results could be...
This trial could show whether intra-operative ultrasound can be used reliably to choose the proximal resection margin during ileocecal resection for terminal ileal Crohn’s disease—information that might affect surgical...
Cure8 could only read part of this source from app.dealroom.co, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Stricture.
Researchers and clinicians are exploring fungi’s role in IBD beyond bacteria. For patients, seeing Candida in stool tests is usually a signal of microbiome disruption rather than proof of fungal infection that requires...
People with IBD and other immune conditions may develop weaker or lower‑quality antibody responses after COVID‑19 vaccination compared with healthy people, and transplant recipients showed the largest impairments. That...
This preclinical study suggests Antarctic krill oil may reduce inflammation and alter the gut microbiome in a mouse model of ulcerative colitis, which could point toward microbiota-targeted nutritional strategies worth...
Measures used in trials and care often miss what patients value most — daily function and quality of life. Learning from IBD and RA could lead to asthma outcome measures and trials that reflect patient priorities, which...
Pathology after fecal diversion can look like active IBD, which affects diagnosis and management of the diverted rectum. This study helps clarify when changes likely reflect diversion alone versus persistent inflammatory...
Fundraisers like this support research, patient programs, and advocacy that can expand resources and advance scientific work relevant to people with Crohn’s disease and ulcerative colitis.
A subcutaneous induction option could make starting risankizumab easier and less burdensome than IV infusions for many people with Crohn's disease, potentially expanding access and convenience.
A strategic, pediatric-focused research agenda helps target studies where children with IBD and related conditions most need better diagnostics, biomarkers, and treatments. Prioritizing multi-center registries and...
A new subcutaneous induction option for risankizumab could make starting IL‑23 therapy more convenient for adults with moderately to severely active Crohn’s disease and expand choices for those who have failed prior...
If approved, a subcutaneous induction option for risankizumab would let eligible adults start and continue treatment without needing an infusion visit, which can be more convenient and reduce infusion-related costs and...
People with UC or IBD may be interested because the study identifies plant-derived compounds that reduce inflammation in lab models of ulcerative colitis and points to molecular pathways relevant to IBD.
Environmental cadmium exposure may alter the gut microbiome’s metabolites (oleic acid) and worsen colitis in mice via FFAR4-linked inflammatory pathways. If similar mechanisms operate in people, this could point to new...
PSC frequently occurs with IBD and has unclear origins; understanding a shared glandular mechanism could help explain the link and point to new research targets relevant to both liver and colon disease.
The paper proposes ISG20 as a shared molecular link between RA and IBD, which could help explain why the two diseases co-occur and point to a candidate biomarker for identifying patients at risk of both conditions.
This study identifies conserved, gut-enriched genes (colonization factors) and shows their repertoires are remodeled in IBD, highlighting functional microbiome changes that could inform future biomarkers or...
Diet quality was linked to gut microbiome features and exploratory differences in inflammatory markers and symptoms in adults with Crohn disease from Puerto Rico; understanding these links may help tailor dietary...
Tools that reliably measure self-care self-efficacy can help clinicians identify IBD patients who may benefit from extra self-management support. A brief, validated 10-item scale is practical for busy clinics and...
Patients and clinicians may notice fewer resources from a major drugmaker focused on a specific T‑cell antigen discovery effort for Crohn’s disease; researchers and investors should see this as a signal about how large...
